Fig 4.

Impact of frailty on JAK inhibitor treatment failure in patients with myelofibrosis. (A) Treatment failure data (defined as per Canadian consensus criteria²⁶) from time of starting JAK inhibitor treatment among 222 patients with myelofibrosis, according to frailty status, defined by a 35‐item cumulative deficit frailty index. (B) Forest plot represents the HRs from the multivariable cox regression analysis for association between frailty status and treatment failure in JAK inhibitor‐treated patients. For all estimates, P ≤ 0·05 was considered statistically significant. ECOG, Eastern Co‐operative Group scale; HCT‐CI, haematopoietic stem cell transplant comorbidity index; DIPSS, Dynamic International Prognostic Scoring System; Int, intermediate; CI, confidence interval; FI, frailty index. [Colour figure can be viewed at wileyonlinelibrary.com]